The biology of lipoprotein(a): From genetics to molecular mechanisms
European Journal of Clinical Investigation · 2026-01 · 56 (1)
DOI: 10.1111/eci.70133 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 03.10.2025. Verfasst von Mark Atallah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Lipoprotein(a), Atherosclerosis, Calcinosis, Aortic Valve Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Lipoprotein(a) [Lp(a)] is a primarily genetically determined, low‐density lipoprotein‐like particle that plays an important role in atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). Despite optimal control of traditional lipid levels, elevated lipoprotein(a) [Lp(a)] remains a significant contributor to residual cardiovascular risk, affecting up to 20% of the global population.
Methods
We performed a literature search of PubMed/Medline and Google Scholar until July 2025 to provide a comprehensive overview of the genetics, structure, metabolism, and molecular mechanisms underlying Lp(a)'s pathogenicity.
Results
Structurally, Lp(a) consists of an LDL‐like core covalently bound to apolipoprotein(a) [apo(a)], a polymorphic glycoprotein characterized by kringle IV type 2 (KIV‐2) repeat variability. This copy number variation is the primary determinant of apo(a) isoform size and plasma Lp(a) levels. Small isoforms are produced more efficiently, resulting in higher concentrations. Lp(a) is synthesized in hepatocytes, and its plasma levels are predominantly governed by production rather than clearance. It carries a high burden of oxidized phospholipids (OxPLs), which confer pro‐inflammatory and pro‐atherogenic properties. Lp(a) promotes arterial inflammation, endothelial dysfunction, monocyte activation and impaired fibrinolysis via competition with plasminogen. It also plays a direct pathogenic role in valvular calcification by delivering OxPLs and autotaxin to valve interstitial cells, triggering osteogenic signaling cascades.
Conclusion
While environmental factors such as inflammation and hormonal status can transiently modulate levels, genetic variation overwhelmingly dictates lifelong Lp(a) burden. As novel agents targeting Lp(a) enter late‐stage clinical trials, mechanistic insights into Lp(a) biology will be essential to risk stratification and future clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Thorsten M Leucker
Förderung
- NHLBI NIH HHS
Zitieren
APA
Atallah, M., Nasrallah, N., Harb, T., Gerstenblith, G., & Leucker, T. M. (2026). The biology of lipoprotein(a): From genetics to molecular mechanisms. European Journal of Clinical Investigation, 56(1). https://doi.org/10.1111/eci.70133
Vancouver
Atallah M, Nasrallah N, Harb T, Gerstenblith G, Leucker TM. The biology of lipoprotein(a): From genetics to molecular mechanisms. European Journal of Clinical Investigation. 2026;56(1). doi:10.1111/eci.70133
BibTeX
@article{Atallah2026,
author = {Atallah, Mark and Nasrallah, Nadim and Harb, Tarek and Gerstenblith, Gary and Leucker, Thorsten M},
title = {The biology of lipoprotein(a): From genetics to molecular mechanisms},
journal = {European Journal of Clinical Investigation},
year = {2026},
volume = {56},
number = {1},
doi = {10.1111/eci.70133}
}
EUVIMED